Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • masterpiece
    Member
    • Mar 2009
    • 40

    cufflinks : difference in --GTF and --GTF-guide result

    Hi all,


    I've run transcriptome data analysis on bacteria samples. However, I'm puzzle on expression result differences between --GTF and --GTF-guide option used when run cufflinks. All parameters that I've used to run both sets are the except for cufflinks, one with --GTF and the other --GTF-guide. Here is the "isoforms.fpkm_tracking" from both run

    cufflinks with --GTF option

    tracking_id class_code nearest_ref_id gene_id gene_short_name tss_id locus length coverage FPKM FPKM_conf_lo FPKM_conf_hi FPKM_status
    PL0001.t01 - - - - NC_006350 0-1116 1116 54.9354 90.6693 83.0938 98.2448 OK
    PL0002.t01 - - - - NC_006350 1160-2375 1215 39.0997 65.3895 59.2786 71.5004 OK
    PL0003.t01 - - - - NC_006350 3113-5096 1983 8.92195 15.1043 12.8893 17.3193 OK
    PL0005.t01 - - - - NC_006350 5868-7209 1341 33.7041 56.7591 51.3899 62.1284 OK
    PL0006.t01 - - - - NC_006350 7527-8013 486 260.334 428.281 398.744 457.818 OK
    PL0010.t01 - - - - NC_006350 13451-13862 411 53.5034 88.5618 72.9061 104.217 OK
    PL0009.t01 - - - - NC_006350 12162-13380 1218 27.5019 46.1215 40.9969 51.2461 OK
    PL0011.t01 - - - - NC_006350 14009-14462 453 181.027 309.998 283.268 336.728 OK
    PL0012.t01 - - - - NC_006350 14616-15096 480 73.6868 122.777 106.793 138.762 OK
    cufflinks with --GTF-guide option

    tracking_id class_code nearest_ref_id gene_id gene_short_name tss_id locus length coverage FPKM FPKM_conf_lo FPKM_conf_hi FPKM_status
    PL0001.t01 - - - - NC_006350 0-1116 1116 0 0 0 0 OK
    PL0002.t01 - - - - NC_006350 1160-2375 1215 0 0 0 0 OK
    PL0003.t01 - - - - NC_006350 3113-5096 1983 0 0 0 0 OK
    PL0005.t01 - - - - NC_006350 5868-7209 1341 0 0 0 0 OK
    PL0006.t01 - - - - NC_006350 7527-8013 486 0 0 0 0 OK
    PL0007.t01 - - - CUFF.160 NC_006350 8394-10668 2274 0 0 0 0 LOWDATA
    PL0008.t01 - - - CUFF.160 NC_006350 10664-12158 1494 0 0 0 0 LOWDATA
    PL0009.t01 - - - CUFF.160 NC_006350 12162-13380 1218 0 0 0 0 LOWDATA
    PL0010.t01 - - - - NC_006350 13451-13862 411 0 0 0 0 OK
    PL0011.t01 - - - CUFF.160 NC_006350 14009-14462 453 0 0 0 0 LOWDATA
    And why some of the genes have FPKM of "0" but at the same time it gives FPKM_status as "OK"?


    - kamal

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Today, 12:17 PM
0 responses
8 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, Yesterday, 11:41 AM
0 responses
10 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
37 views
0 reactions
Last Post SEQadmin2  
Working...